140Tip Brightline-4: A Phase III Open-Label, Single-Arm, Multicentre Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828), an MDM2-p53 Antagonist, in Patients with Treatment-Naïve or Pretreated Advanced Dedifferentiated Liposarcoma